Dr Reddy's Laboratories Shares Rise After Acquiring Haleon’s Nicotine Replacement Therapy

Dr Reddy's Laboratories Shares Rise After Acquiring Haleon’s Nicotine Replacement Therapy

A also set a target of Rs 6,500 for its shares. Interestingly, at the halfway mark of the intraday trading session, the company shares zoomed by over 2 per cent, taking them past the previously mentioned target of Rs 6,500.

G R MukeshUpdated: Wednesday, July 03, 2024, 01:19 PM IST
article-image

Hyderabad-based Dr Reddy Laboratories, one of the more-noticed names in the pharma business, has been in the headlines for the past few days now. In a recent development, the company shares jumped over 2 per cent in intraday trade on Wednesday, July 3.

Dr Reddy's Acquires NRT

This development came to pass after the pharma company's acquisition plans for British pharma company Haleon's Nicotine Replacement Therapy were made public.

In addition, this rise in shares comes just a few days after stock broking company Prabhudas Lilladher issued a Buy call for the company shares.

In addition, this rise in shares comes just a few days after stock broking company Prabhudas Lilladher issued a Buy call for the company shares. |

The company is reported to have spent Rs 5,301 crore on the deal. This move is expected to help the company's over-the-counter business.

In addition, this rise in shares comes just a few days after stockbroking company Prabhudas Lilladher issued a 'Buy' call for the company's shares.

The brokerage company also set a target of Rs 6,500 for its shares. Interestingly, at the halfway mark of the intraday trading session, the company shares zoomed by over 2 per cent, taking them past the previously mentioned target of Rs 6,500.

When it comes to the company's Q4 performance, the company's overall revenue came up to Rs 7,083 crore in the final quarter of FY24.

This marked a 12.5 per cent jump in its previous cycle, when it was at Rs 6,297 crore. In addition, it had a consolidated net profit of Rs 1,307 crore. However, according to reports, it was still below estimates.

This marked a 12.5 per cent jump in its previous cycle, when it was at Rs 6,297 crore. In addition, it had a consolidated net profit of Rs 1,307 crore. However, according to reports, it was still below estimates. | Representational Image/Pixabay

Shares Rise By Over 1%

This marked a 12.5 per cent jump in its previous cycle, when it was at Rs 6,297 crore. In addition, it had a consolidated net profit of Rs 1,307 crore. However, according to reports, it was still below estimates.

After a great start to the day, Dr Reddy's Laboritaries shares, which surged by over 2 per cent, tapered away and lost their momentum slightly as the surge declined marginally. At 13:11, the company shares increased by 1.37 per cent or Rs 87.10, taking the cumulative value to Rs 6,457.35 per share.

Meanwhile, some of the other pharma stocks are trading in red. Divi Laboratories and Cipla declined by under 0.50 per cent, while Sun Pharma is trading at an increase of 0.056 per cent.  

RECENT STORIES

Adani Wilmar Reports 13% Volume Growth In June Quarter

Adani Wilmar Reports 13% Volume Growth In June Quarter

Tomato Prices Soar to ₹70-80 per kg in Delhi Amid Heatwave-Induced Supply Shortage

Tomato Prices Soar to ₹70-80 per kg in Delhi Amid Heatwave-Induced Supply Shortage

Retro Style Meets Modern Performance: BMW R 12 nineT

Retro Style Meets Modern Performance: BMW R 12 nineT

Mastering Lean Manufacturing With Amey Phatale: Enhancing Operations In The Automotive Industry

Mastering Lean Manufacturing With Amey Phatale: Enhancing Operations In The Automotive Industry

India's Forex Reserves Decline $1.71 Billion To $651.99 Billion

India's Forex Reserves Decline $1.71 Billion To $651.99 Billion